A cohort study to examine the effect of 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix, Registered Trademark) on the frequency of non-typeable Haemophilus influenzae (NTHi) infection in the upper and lower airways of children
Does prior immunization with PHiD-CV influence the frequency of NTHi detection in the upper and lower airways in children undergoing bronchoscopy?
Menzies School of Health Research, Charles Darwin University
316 participants
Apr 19, 2011
Observational
Conditions
Summary
The aims of our study are to: 1. Determine the frequency of NTHi infection (defined by >10E4 cfu/ml BAL) in the lower airways of children who have received PHiD-CV; 2. Determine the frequency of NTHi carriage in the upper airways of children who have received PHiD-CV; and 3. Evaluate the influence of PHiD-CV on the systemic adaptive immunity to NTHi in`children with chronic suppurative lung disease.
Eligibility
Inclusion Criteria2
- Subjects: Children undergoing bronchoscopy who have had at least one PHiD-CV dose more than a month before bronchoscopy
- Comparator: Children undergoing bronchoscopy who have not had any PHiD-CV dose (Brisbane and/or Darwin)
Exclusion Criteria4
- Previously enrolled
- Cystic fibrosis
- Immunodeficiency
- Interstitial lung disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PHiD-CV given as per the Northern Territory infant immunization schedule. Child is not observed for any set period of time. Observation consist of the bronchoscopy alveolar lavage results at the time-point when the procedure is undertaken for clinical purposes and not for research purposes. Thus there is no time limit of the observation period as the bronchoscopy is undertaken when the paediatrician (not related to the study) deemed the procedure is necessary
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000743662